NO20064183L - Less immunogenic binding molecules - Google Patents
Less immunogenic binding moleculesInfo
- Publication number
- NO20064183L NO20064183L NO20064183A NO20064183A NO20064183L NO 20064183 L NO20064183 L NO 20064183L NO 20064183 A NO20064183 A NO 20064183A NO 20064183 A NO20064183 A NO 20064183A NO 20064183 L NO20064183 L NO 20064183L
- Authority
- NO
- Norway
- Prior art keywords
- amino acid
- binding molecules
- molecules
- nucleic acid
- acid sequence
- Prior art date
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Sammendrag Den foreliggende oppfinnelsen tilveiebringer et spesifikt bindingsmolekyl, hvor nevnte molekyl omfatter eller består av minst to domener hvorved ett av nevnte minst to domener spesifikt binder til/interagerer med det humane CD3-komplekset og det nevnte domenet omfatter en aminosyresekvens av en antistoff derivert lett kjede, hvor nevnte aminosyresekvens er en spesielt identifisert aminosyresekvens som omfatter spesifikke aminosyresubstitusjoner, og et andre domene er eller inneholder minst ett ytterligere antigen-interagerende-sete og/eller minst ett ytterligere effektordomene. Oppfinnelsen tilveiebringer videre nukleinsyremolekyler som koder for de bispesifikke bindingsmolekylene av oppfinnelsen, vektorer som omfatter nevnte ukleinsyremolekyler og vertsceller transformert eller transfektert med nevnte vektorer. Videre angår oppfinnelsen en fremgangsmåte for produksjonen av bispesifikke bindingsmolekyler av oppfinnelsen og sammensetninger som omfatter de bispesifikke bindingsmolekylene av oppfinnelsen, nukleinsyremolekylene av oppfinnelsen eller vertscellene av oppfinnelsen.SUMMARY The present invention provides a specific binding molecule, wherein said molecule comprises or consists of at least two domains wherein one of said at least two domains specifically binds to / interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain , wherein said amino acid sequence is a specifically identified amino acid sequence comprising specific amino acid substitutions, and a second domain is or contains at least one additional antigen-interacting site and / or at least one additional effector domain. The invention further provides nucleic acid molecules encoding the bispecific binding molecules of the invention, vectors comprising said nucleic acid molecules and host cells transformed or transfected with said vectors. Furthermore, the invention relates to a process for the production of bispecific binding molecules of the invention and compositions comprising the bispecific binding molecules of the invention, the nucleic acid molecules of the invention or the host cells of the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05715354A EP1716178B1 (en) | 2004-02-16 | 2005-02-16 | Less immunogenic binding molecules |
PCT/EP2005/001573 WO2005077982A1 (en) | 2004-02-16 | 2005-02-16 | Less immunogenic binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064183L true NO20064183L (en) | 2006-11-08 |
Family
ID=37564058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064183A NO20064183L (en) | 2005-02-16 | 2006-09-15 | Less immunogenic binding molecules |
Country Status (1)
Country | Link |
---|---|
NO (1) | NO20064183L (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2370467B1 (en) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
US11472886B2 (en) | 2008-10-01 | 2022-10-18 | Amgen Research (Munich) Gmbh | Cross-species-specific PSMAxCD3 bispecific single chain antibody |
-
2006
- 2006-09-15 NO NO20064183A patent/NO20064183L/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2370467B1 (en) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
US11472886B2 (en) | 2008-10-01 | 2022-10-18 | Amgen Research (Munich) Gmbh | Cross-species-specific PSMAxCD3 bispecific single chain antibody |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1716178T3 (en) | Less immunogenic binding molecules | |
CY1121536T1 (en) | HUMAN ANTIBODIES AGAINST ALPHA-SYNUCLEIN | |
CY1118303T1 (en) | SPECIFICATION FOR CROSS-CUTTING SINGLE SPECIAL SINGLE-SINGLE ANTIBODY PSMAXCD3 | |
DK1752471T3 (en) | Synthetic immunoglogulin domains with binding properties that are modified in regions of the molecule that differ from the complementarity determining regions | |
NO20091283L (en) | Human antibodies that bind CXCR4 and its applications | |
MX2009013328A (en) | Methods of modifying antibodies, and modified antibodies with improved functional properties. | |
NZ717429A (en) | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly | |
CY1116525T1 (en) | BINDING STRENGTHENING FACTORS | |
CL2011000084A1 (en) | Monoclonal antibody or antigen binding fragment thereof that binds to human cytomegalovirus (hcmv); nucleic acid molecule that encodes it; vector; host cell; Method of production; and composition that understands it. | |
NO20083268L (en) | Antibodies designated for HER-3 and uses thereof | |
AR060583A1 (en) | ANTIBODY OF HUMANIZED C- KIT | |
NO20092285L (en) | Human monoclonal antibodies to BTLA and methods of use | |
NO20090406L (en) | Antigen-binding molecules that bind EGFR, vectors encoding these, and uses thereof | |
DK1819830T3 (en) | Methods for antibody generation | |
BRPI0812878C1 (en) | isolated antibody or functional part thereof, vector, method for producing an antibody or a functional part thereof, for producing an antibody-producing cell and for producing an antibody capable of specifically binding to rsv, composition, and use of an antibody or functional part of it or of a composition or vector | |
CA2808482C (en) | Methods for the generation of multispecific and multivalent antibodies | |
MX2009009450A (en) | He4 monoclonal antibodies and methods for their use. | |
NO20064866L (en) | IRTA-5 antibodies and their use | |
TR201909531T4 (en) | ANTI-IL-17 ANTIBODIES USING ANKILOSANE SPONDILITE TREATMENT METHODS | |
TN2011000253A1 (en) | Process for the modulation of the antagonistic activity of a monoclonal antibody | |
ATE497508T1 (en) | ANTIBODIES DIRECTED AGAINST THE MAMMAL EAG1 ION CHANNEL PROTEIN | |
NO20071432L (en) | Method for concentration of antibodies or therapeutic products thereof. | |
NO20081328L (en) | Modified antigen-binding molecules with altered cell signaling activity | |
BR112012024964A2 (en) | psmaxcd3 biospecific single chain antibody of specific cross species, their preparation process, their use, vector, pharmaceutical composition and kit | |
MX2009008608A (en) | Monoclonal anti-cxcl13 antibodies. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |